

1 **THE ROLE OF PROSTATE INFLAMMATION AND FIBROSIS IN LOWER URINARY TRACT**
2 **SYMPTOMS**

3 Wade A. Bushman, Travis J. Jerde

4 Department of Urology; University of Wisconsin; Madison, WI, 53792, Bushman@urology.wisc.edu.

5 Corresponding Author

6 Department of Pharmacology and Toxicology; Indiana University School of Medicine; Indianapolis, IN,
7 46202.

8

This is the author's manuscript of the article published in final edited form as:

Bushman, W. A., & Jerde, T. J. (2016). The role of prostate inflammation and fibrosis in lower urinary tract symptoms. *American Journal of Physiology - Renal Physiology*, 311(4), F817–F821.
<https://doi.org/10.1152/ajprenal.00602.2015>

9 **Abstract**

10

11 Lower urinary tract symptoms (LUTS) in aging men are extremely common. They have historically been
12 attributed to benign prostatic hyperplasia (BPH), enlargement of the prostate and bladder outlet
13 obstruction. However, recent studies have revealed acute and chronic inflammation to be highly
14 associated with LUTS, correlated with prostatic enlargement and implicated prostate fibrosis as a
15 contributing cause of bladder outlet obstruction. This review examines the evidence implicating
16 inflammation and fibrosis in BPH/LUTS. It identifies potential mechanisms by which inflammation may
17 drive nociceptive signaling as well as hyperplastic growth and fibrosis and identifies targets for
18 pharmacologic intervention. This is a promising area for research and development of novel therapies
19 to prevent or more effectively treat LUTS in aging men.

20

21 **Background:** Lower urinary tract symptoms (LUTS) are common in aging men and include obstructive
22 symptoms such as weak urinary stream, straining to void, and a sense of incomplete emptying as well
23 as irritative symptoms such as frequency, urgency, nocturia. These symptoms have generally been
24 attributed to prostatic enlargement and an increase in outlet resistance with secondary effects on
25 bladder function. Benign prostatic hyperplasia (BPH) is an age-related, androgen-dependent
26 progressive enlargement of the prostate gland resulting from a non-malignant proliferative process that
27 includes both epithelial and stromal elements. A contribution of prostatic enlargement to development
28 of LUTS is unequivocal. However, recent studies have shown that development of LUTS is multi-
29 factorial. Changes in smooth muscle tone in the prostate and bladder neck may increase outlet
30 resistance independent of significant enlargement (Nickel, 1999). Age-related decrease in detrusor
31 contractility and primary detrusor over-activity contribute significantly to lower urinary tract symptoms.
32 Recently, prostatic inflammation has been found to be associated with prostatic enlargement, severity
33 of LUTS and symptomatic progression. That is the focus of this review.

34

35 **Prostate inflammation:** Prostatic inflammation is evident by inflammatory cells infiltrating the prostatic
36 stroma, epithelium, and/or prostate glands (Cotran RS et al, 1999; Nickel et al., 2008). Acute and
37 chronic inflammation has been identified in 40-50% of prostatic samples obtained by biopsy, surgery, or
38 autopsy (DeLongchamps et al., 2008; Kohnen and Drach, 1979; Theyer et al., 1992; Steiner et al., 1994;
39 Kramer et al., 2006; Di Silverio, et al., 2003). Chronic inflammation is more common than acute
40 inflammation (78% versus 15%, respectively; Moreira et al., 2014). The etiology of prostatic
41 inflammation is likely multi-factorial. Urine refluxes freely into the prostatic ducts (Kirby, 1982) and
42 provides a route for bacterial colonization. (Weiss, 1983; Krieger and Riley, 2002). Other potential
43 causes include viruses, dietary components, changes in serum testosterone and estrogen levels,
44 autoimmune mechanisms, and reflux of noxious chemicals in the urine (DeMarzo et al., 2007;
45 Gandaglia et al., 2013). In addition, prostate inflammation can be triggered by metabolic alterations
46 including metabolic syndrome and dyslipidemia (Vignozzi et al 2016; DeNunzio et al 2012; Freeman

47 and Solomon 2011). All told, these studies point to a systemic and metabolic cause for prostatic
48 inflammation.

49

50 **Inflammation is more common in men with BPH/LUTS and correlates with symptom severity and**

51 **risk for progression.** In a prospective study of autopsy specimens obtained from 93 men with
52 histological evidence of BPH, chronic inflammation was found (primarily in the transitional zone) in 75%
53 of prostates examined compared to 55% of prostates not affected by BPH (DeLongchamps 2008).

54 Evidence of inflammation on baseline biopsy in the Medical Therapy of Prostate Symptoms (MTOPS)
55 trial correlated with prostate volume (41 vs 37 cc; $p=0.0002$) and greater risk for symptomatic
56 progression, urinary retention and need for surgery (Roehrborn, 2006). It has been postulated that
57 inflammation may contribute to prostate enlargement by inducing hyperplasia. However, it has also
58 been postulated that prostatic inflammation could cause urinary frequency and urgency by directly
59 influencing bladder sensation and detrusor function (Geppetti, 2008). Pelvic organs share innervation
60 and it has been shown that inflammation of one pelvic organ can produce cross-sensitization of other
61 pelvic viscera (Qin, 2005; Rudick, 2007; Ustinova, 2007; Ustinova, 2006). This has been postulated to
62 occur, in part, by triggering activation of afferent sensory nerves (Candenas, 2005; Lecci, 2001; Maggi,
63 1997). Recently we showed that isolated prostate inflammation in the laboratory mouse produces a
64 significant increase in voiding frequency (Lee et al., 2015). The anatomic basis for this may be
65 convergent innervation of the bladder and prostate: afferent neurons in the lumbosacral dorsal root
66 ganglia providing afferent innervation of the both the prostate and bladder (manuscript submitted).
67 These observations resonate with the selective correlation of inflammation with irritative LUTS in the
68 REDUCE trial (Nickel et al., 2008).

69

70 **Prostatic fibrosis and bladder outlet obstruction:** While prostatic enlargement correlates with
71 increased urethral resistance and LUTS (Bushman, 2009), many men experience bladder outlet
72 obstruction and symptoms in the absence of significant prostatic enlargement (Blaivas, 1996;

73 Bushman, 2009). Increased adrenergic tone of smooth muscle in the prostate may be a contributing
74 factor, but the frequent ineffectiveness of medical therapy with alpha-blockers argues for additional
75 mechanisms. It has been speculated that fibrosis of the prostate may increase urethral resistance and
76 several studies have provided evidence for periurethral fibrosis, decreased elastin and changes in
77 tissue compliance (Bercovich et al., 1999; Diavan et al. 1999; Morrison et al., 2000; Ma et al., 2012;
78 Rodriguez-Nieves and Macoska 2013; Cantiello et al. 2013; Bauman et al. (2014). The etiology of
79 prostate fibrosis is uncertain but chronic inflammation is an obvious candidate. Studies in the mouse
80 have shown that prostate inflammation does induce an increase in collagen content (Wong et al.,
81 2014a) and there is a suggestion in human studies of a correlation between inflammation and fibrosis
82 (Cantiello et al., 2013).

83

84 **Cells and mechanisms.** The majority of infiltrating leukocytes in the inflamed human prostate are
85 chronically-activated T lymphocytes and macrophages (Theyer et al. 1992; Steiner et al. 2003). Mouse
86 models of inflammation exhibit very similar infiltrative components as inflamed human prostates
87 (Boehm et al 2012; Haverkamp et al 2011). Th1 cells regulate the immune response to intracellular
88 pathogens via IFN and IL-2. Th2 cells produce IL-4, IL-13 and IL-5 and regulate the hypersensitivity
89 response. Th17 cells are responsible for host defense against extracellular pathogens (Rautajoki et al.
90 2008) through IL-17 and IL-21. Resident epithelial and stromal cells express several toll-like receptors
91 including TLR-4, TLR-5, TLR-7 and TLR-9, and also produce IL-1, IL-6, and IL-15 during inflammation
92 (Kramer & Marberger 2006). Prostatic epithelial cells express class II MHC molecules that participate in
93 organ-specific inflammation (Penna et al. 2009), resulting in the production of IL-6, IL-8 and CXCL10
94 and leukocyte recruitment (Penna et al. 2009). Stromal cells express CD80, CD86, CD40, and CD134L
95 (Penna et al.2009) and activate T lymphocytes directly. These activities contribute to a chronic state of
96 inflammation.

97

98 The cytokines and growth factors highly expressed in BPH include IL-1, IL-6, IL-8, IL-15, IL-17, IFN γ ,
99 TGF β , FGF2 and 7, and IGF-1 (Handisurya et al 2001; Steiner et al 2003; Hahn et al. 2014; Giri and
100 Ittman 2001). These cytokines have been proposed as a link between chronic prostate inflammation
101 and prostatic hyperplasia because they intersect with critical stromal and epithelial paracrine signaling
102 pathways that regulate prostate growth. The Jak-STAT signaling pathway is induced by a number of
103 these cytokines, most notably IL-6 and IL-1 (Shankar et al 2014; Jerde and Bushman 2009; Verma et al
104 2014). The NF κ B signaling pathway is a major player in inflammatory signaling (Bouraoui et al 2012)
105 and is induced by IL-1 downstream of MyD88. Interesting, androgen receptor signaling also results in
106 activation of this pathway (Atawia et al 2014). Interesting, androgens have also been shown to play a
107 critical role as anti-inflammatory agents, as men on anti-androgen therapy develop prostatic
108 inflammation; this has been corroborated in mouse models (Izumi et al 2014). Phosphoinositide
109 signaling is the major pathway downstream of IGF-1 and is highly activated in the epithelium of BPH
110 and inflamed prostates (Hahn et al 2014). Secreted ligands of G-protein-coupled receptors (GPCRs)
111 including prostaglandins, epinephrine, acetylcholine, histamine, and kinins activate pathways that
112 include PKCs, cAMP, nitric oxide (NO), and phosphodiesterases (PDEs) during prostatic inflammation.

113

114 **Opportunities for improving care.** Recent studies of BPH/LUTS strongly suggest it to be a complex
115 symptomatic condition with a multifactorial etiology. Improvements in diagnosis and treatment of
116 BPH/LUTS will hinge upon finding methods to sub-classify patients according to etiology and to select
117 the most efficacious treatment. In this regard it is notable that there is evidence suggesting that
118 patients with high-grade prostate inflammation are less likely to respond to standard medical therapy
119 (Kwon et al., 2010). If this is true, then non-invasive biomarkers of inflammation would be useful to
120 identify patients likely to respond to medical therapy and at greater risk for symptomatic progression
121 and urinary retention. Greer et al. (2015) used liquid chromatography mass spectrometry to compare
122 over 800 proteins in BPH/LUTS patients and controls. Gene ontology (GO) analysis of the 50

123 differentially expressed proteins proteins showed revealed many were involved in inflammatory
124 responses and implicated in fibrosis. Additionally, targeting the noted metabolic alterations associated
125 with BPH-LUTS (Vignozzi et al 2016) could have the systemic effect of reducing prostatic inflammation
126 in patients with LUTS, and therefore could have a beneficial impact on LUTS severity and progression.

127

128 **Novel therapeutic targets involving inflammatory signaling.** A recent comprehensive review and
129 meta-analysis by Kahokehr and associates demonstrates that there is a therapeutic benefit to treating
130 BPH with anti-inflammatories (Kahokehr et al 2013). Additionally, the specific COX-2 inhibitor celecoxib
131 has been shown to reduce BPH symptomology (Falihatkar et al 2008). This provides proof-of-principle
132 for efficacy or therapeutically targeting prostate inflammation and impels the search for therapies to
133 target inflammatory pathways in BPH.

134

135 The new awareness of inflammation's role in BPH has led to speculation that established medical
136 therapies for BPH may be related to secondary anti-inflammatory effects. **[Table 1.]** Alpha-adrenergic
137 antagonists are generally considered to act by relaxing the smooth muscle of the bladder neck and
138 prostate but could more generally block the actions of epinephrine induced during prostatic
139 inflammation. The 5-alpha-reductase inhibitor finasteride interferes with androgen action in the
140 prostate, but it also has anti-nociceptive and anti-inflammatory actions (Duborija-Kovacevic et al. 2008).

141 The phosphodiesterase type-5 (PDE5) inhibitor tadalafil has been approved for treatment of BPH-
142 LUTS. PDE5 inhibitors increase nitric oxide synthase (NOS) and NO activity, inactivate cGMP-
143 mediated p-kinase, and decrease of autonomic hyperactivity in the bladder (Kang et al. 2007).

144 However, PDE activity is induced during inflammation and part of the efficacy of PDE5 inhibitors could
145 be due to anti-inflammatory effects. Indeed, a recent study showed PDE5 inhibitors have substantial
146 anti-inflammatory activity in the prostate (Vignozzi et al, 2013; Peixoto et al. 2015). The role of
147 histamine in neurogenic inflammation is well-established (Rosa and Fantozzi, 2013), and given the
148 strong neuronal component to prostatic inflammation, it is possible that histamine antagonism may be

149 effective as anti-inflammatories in the prostate. Similarly, tachykinins and calcitonin gene-related
150 peptide (CGRP) are neuropeptides present in the prostate, and are highly produced during neurogenic
151 inflammation. Both are involved in prostatic and bladder smooth muscle contraction (Buljubasich et
152 al.1999; Ventura et al., 2000). Similar to the sensory neuropeptides, endothelins are neurogenic
153 inflammation-produced peptides involved in nerve-mediated contractions (Lau et al. 1999), and
154 blockade of ET receptors circumvents inflammation-induced contraction as well as proliferation of
155 resident cells (Saita et al. 1998)

156

157 **Fibrosis as a target of prevention or treatment.** Recent evidence suggesting prostatic fibrosis plays
158 a central role in the development of bladder outlet obstruction in aging men begs the question – can
159 fibrosis be prevented or reversed? Efforts to prevent fibrosis will depend on identifying the actual
160 etiologies and natural history of changes in prostate collagen and elastin content. This is a fertile area
161 for investigation. We have shown that fibrosis of the mouse prostate induced by inflammation of limited
162 duration is partially reversible (Wong et al., 2014b), however, the reversibility of fibrosis in the human
163 prostate has not been examined. Clearly, proving the associations of inflammation, fibrosis and bladder
164 outlet obstruction and then development of medical or minimally invasive therapies to both prevent and
165 reverse prostate fibrosis will be a research priority.

166

167

- 168 1. Atawia RT, Mosli HH, Tadros MG, Khalifa AE, Mosli HA, Abdel-Naim AB. Modulatory effect of
169 silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia:
170 emphasis on PTEN, HIF-1 α , and NF- κ B. *Naunyn Schmiedebergs Arch Pharmacol.* 387: 1131-
171 1140, 2014.
- 172 2. Bauman TM, Nicholson TM, Abler LL, Eliceiri KW, Huang W, Vezina CM, Ricke WA.
173 Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic
174 hyperplasia nodules. *PLoS One.* 9(10): e109102. doi:10.1371/journal.pone.0109102, 2014.
- 175 3. Bercovich E, Barabino G, Pirozzi-Farina F, Deriu M. A multivariate analysis of lower urinary tract
176 ageing and urinary symptoms: the role of fibrosis. *Arch Ital Urol Androl.* 71(5): 287-292, 1999.
- 177 4. Blaivas JG. Obstructive uropathy in the male. *Urol Clin North Am.* 23(3): 373-384, 1996.
- 178 5. Boehm BJ, Colopy SA, Jerde TJ, Loftus CJ, Bushman W. Acute bacterial inflammation of the
179 mouse prostate. *Prostate.* 72(3): 307-317, 2012.
- 180 6. Bouraoui Y, Ben Jemaa A, Rodriguez G, Ben Rais N, Fraile B, Paniagua R, Sellemi S, Royuela
181 M, Oueslati R. Profile of NF- κ Bp(65/NF κ Bp50) among prostate specific antigen sera levels in
182 prostatic pathologies. *Pathol Biol.* 60(5): 301-305, 2012.
- 183 7. Buljubasich S, Lau WA, Pennefather JN, Ventura S. An immunohistochemical and
184 pharmacological study of tachykinins in the rat and guinea-pig prostate glands. *Eur J Pharmacol*
185 380: 137–144, 1999.
- 186 8. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. *Urol*
187 *Clin North Am.* 36(4):403-415, 2009.
- 188 9. Candenias L, Lecci A, Pinto FM, Patak E, Maggi CA, Pennefather JN. Tachykinins and
189 tachykinin receptors: effects in the genitourinary tract. *Life Sci.* 76: 835-862, 2005.
- 190 10. Cantiello F, Cicione A, Salonia A, Autorino R, Tucci L, Madeo I, Damiano R. Periurethral fibrosis
191 secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort
192 study. *Urology.* 81(5): 1018-1023, 2013.

- 193 11. Cotran RS, Kumar V, Robbins SL. Prostatitis in Robbins SL (ed): Robbins' Pathologic Basis of
194 Disease, 6th ed. Philadelphia, WB Saunders; pp 1025–1027, 1999.
- 195 12. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, Jumbelic M,
196 Haas GP. Evaluation of prostatitis in autopsied prostates—is chronic inflammation more
197 associated with benign prostatic hyperplasia or cancer? *J Urol* .179: 1736-1740, 2008.
- 198 13. DeMarzo A. Inflammation in Prostate Carcinogenesis. *Nature Reviews Cancer* 7: 256-269,
199 2007.
- 200 14. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between
201 metabolic syndrome and prostatic diseases. *Eur Urol*. 61(3): 560-70, 2012.
- 202 15. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A. Distribution
203 of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign
204 prostatic hyperplasia: a retrospective analysis. 43:164-175, *Eur Urol*, 2003.
- 205 16. Djavan B, Lin V, Seitz C, Kramer G, Kaplan P, Richier J, Marberger M, McConnell JD. Elastin
206 gene expression in benign prostatic hyperplasia. *Prostate*. 40(4): 242-247, 1999.
- 207 17. Duborija-Kovacevic N, Jakovljevic V, Sabo A, Tomic Z. Anti-nociceptive and anti-inflammatory
208 properties of 5alpha-reductase inhibitor finasteride in experimental animals. *Eur J Drug Metab*
209 *Pharmacokinet*. 33: 181-186, 2008.
- 210 18. Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN. Celecoxib for treatment of
211 nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind,
212 placebo-controlled study. *Urology*. 72: 813-816, 2008.
- 213 19. Freeman MR, Solomon KR. Cholesterol and benign prostate disease. *Differentiation*. 82: 244-
214 252, 2011.
- 215 20. Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F.
216 The role of chronic prostatic inflammation in the pathogenesis and progression of benign
217 prostatic hyperplasia (BPH). *BJU Int*. 112(4):432-441, 2013.

- 218 21. Geppetti P, Nassini R, Materazzi S, Benemei S. The concept of neurogenic inflammation. *BJU*
219 *Internat.*; 101(3): 2-6, 2008.
- 220 22. Gerstenbluth RE, Seftel AD, MacLennan GT, Rao RN, Corty EW, Ferguson K, Resnick MI.
221 Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2
222 in areas of inflammation. *J Urol*; 167: 2267-2270, 2002.
- 223 23. Giri D, Ittmann M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and
224 epithelial growth factor in benign prostatic hyperplasia. *Am J Pathol.* 159: 139–47, 2001.
- 225 24. Greer T, Hao L, Nechyporenko A, Lee S, Vezina CM, Ricke WA, Marker PC, Bjorling DE,
226 Bushman W, Li L. Custom 4-Plex DiLeu Isobaric Labels Enable Relative Quantification of
227 Urinary Proteins in Men with Lower Urinary Tract Symptoms (LUTS). *PLoS One.* 10(8):
228 e0135415, 2015.
- 229 25. Hahn AM, Myers JD, McFarland EK, Lee S, Jerde TJ. Interleukin-driven insulin-like growth
230 factor promotes prostatic inflammatory hyperplasia. *J Pharmacol Exp Ther.* 351(3): 605-615,
231 2014.
- 232 26. Handisurya A, Steiner GE, Stix U, Ecker RC, Pfaffeneder-Mantai S, Langer D, Kramer G,
233 Memaran-Dadgar N, Marberger M. Differential expression of interleukin-15, a pro-inflammatory
234 cytokine and T-cell growth factor, and its receptor in human prostate. *Prostate.* 49(4): 251-262,
235 2001.
- 236 27. Haverkamp JM, Charbonneau B, Crist SA, Meyerholz DK, Cohen MB, Snyder PW, Svensson
237 RU, Henry MD, Wang HH, Ratliff TL. An inducible model of abacterial prostatitis induces antigen
238 specific inflammatory and proliferative changes in the murine prostate. *Prostate.* 71: 1139-1150,
239 2011.
- 240 28. Izumi K, Li L, Chang C. Androgen receptor and immune inflammation in benign prostatic
241 hyperplasia and prostate cancer. *Clin Investig.* 4(10):935-950, 2014.
- 242 29. Jerde TJ, Bushman W. IL-1 induces IGF-dependent epithelial proliferation in prostate
243 development and reactive hyperplasia. *Sci Signal.* 2(86): ra49, 2009.

- 244 30. Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary
245 tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of
246 randomized controlled trials. *BJU Int.* 111: 304-311, 2013.
- 247 31. Kang KK, Kim JM, Yu JY, Ahn BO, Yoo M, Kim YC. Effects of phosphodiesterase type 5
248 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of
249 benign prostate hyperplasia. *Int J Urol.* 14: 946-951, 2007.
- 250 32. Kirby RS, Lowe D, Bultitude MI and Shuttleworth KE. Intra-prostatic urinary reflux: an
251 aetiological factor in abacterial prostatitis. *Br J Urol.* 54:729-31, 1982.
- 252 33. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and
253 bacterial study. *J Urol.* 121:755-760, 1979.
- 254 34. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune
255 inflammatory disease? *Eur Urol.* 51(5):1202-1216, 2007.
- 256 35. Krieger JN, Riley DE. Prostatitis: what is the role of infection. *Int J Antimicrob* 19: 475-479,
257 2002.
- 258 36. Kwon YK1, Choe MS, Seo KW, Park CH, Chang HS, Kim BH, Kim CI. The effect of
259 intraprostatic chronic inflammation on benign prostatic hyperplasia treatment. *Korean J Urol.*
260 51(4): 266-270, 2010.
- 261 37. Lau WA, Cox SL, Pennefather JN, Mitchelson FJ. Pharmacological characterization of
262 endothelin receptor subtypes in the guinea-pig prostate gland. *Br J Pharmacol* 127: 1091–1098,
263 1999.
- 264 38. Lecci A, Maggi CA. Tachykinins as modulators of the micturition reflex in the central and
265 peripheral nervous system. *Regul Pept.* 101: 1-18, 2001.
- 266 39. Lee S, Yang G, Bushman W. Prostatic inflammation induces urinary frequency in adult mice.
267 *PLoS One.*10(2): e0116827, 2015.

- 268 40. Ma J, Gharaee-Kermani M, Kunju L, Hollingsworth JM, Adler J, Arruda EM, Macoska JA.
269 Prostatic fibrosis is associated with lower urinary tract symptoms. *J Urol.* 188(4): 1375-1381,
270 2012.
- 271 41. Maggi CA. The effects of tachykinins on inflammatory and immune cells. *Regul Pept.* 70: 75-
272 90, 1997.
- 273 42. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, Freedland SJ.
274 Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men
275 undergoing repeat prostate biopsy: results from the REDUCE study. *Cancer.* 120(2): 190-196,
276 2014.
- 277 43. Morrison C, Thornhill J, Gaffney E. The connective tissue framework in the normal prostate,
278 BPH and prostate cancer: analysis by scanning electron microscopy after cellular digestion. *Urol*
279 *Res.* (5): 304-307, 2005.
- 280 44. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign
281 prostatic hyperplasia. *BJU Internat.* 84: 976–981,1999.
- 282 45. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The
283 relationship between prostate inflammation and lower urinary tract symptoms: examination of
284 baseline data from the REDUCE trial. *Eur Urol.* 54: 1379-1384, 2008.
- 285 46. Peixoto CA, Gomes FO. The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a
286 review. *J Inflamm (Lond).* 12: 54, 2015.
- 287 47. Penna, G., Fibbi, B., Amuchastegui, S., Cossetti, C., Aquilano, F., Laverny, G., Gacci, M.,
288 Crescioli, C., Maggi, M. & Adorini, L. Human Benign prostatic hyperplasia stromal cells as
289 inducers and targets of chronic immuno-mediated inflammation. *Journal of Immunology* 182,
290 4056–4064, 2009.
- 291 48. Qin C, Malykhina AP, Akbarali HI, Foreman RD. Cross-organ sensitization of lumbosacral spinal
292 neurons receiving urinary bladder input in rats with inflamed colon. *Gastroenterology.*129:
293 1967-1978, 2005.

- 294 49. Rautajoki, K. J., Kylaniemi, M. K., Raghav, S. K., Rao, K. & Lahesmaa, R. An insight into
295 molecular mechanisms of human T helper cell differentiation. *Annals of Medicine* 40, 322–335;
296 2008.
- 297 50. Rodriguez-Nieves JA, Macoska JA. Prostatic fibrosis, lower urinary tract symptoms, and BPH.
298 *Nat Rev Urol.* 10(9): 546-550, 2013.
- 299 51. Rosa AC, Fantozzi R. The role of histamine in neurogenic inflammation. *Br J Pharmacol.* 170:
300 38-45, 2013.
- 301 52. Saita Y, Yazawa H, Koizumi T, Morita T, Tamura T, Takenaka T Mitogenic activity of endothelin
302 on human cultured prostatic smooth muscle cells. *Eur J Pharmacol* 349: 123–128, 1998.
- 303 53. Shankar E, Bhaskaran N, MacLennan GT, Liu G, Daneshgari F, Gupta S. Inflammatory
304 Signaling Involved in High-Fat Diet Induced Prostate Diseases. *J Urol Res.* 2: 1-10. 2015.
- 305 54. Steiner G, Gessl A, Kramer G, Schöllhammer A, Förster O, Marberger M. Phenotype and
306 function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. *J*
307 *Urol.* 151: 480–484, 1994.
- 308 55. Steiner, G. E., Stix, U., Handisurya, A., Willheim, M., Haitel, A., Reithmayr, F. Paikl, D., Ecker,
309 R.C., Hrachowitz, K., Kramer, G., Lee, C., Marberger, M. Cytokine expression pattern in benign
310 prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA
311 profile in prostatic tissue. *Laboratory Investigation.* 83, 1131–1146; 2003.
- 312 56. Theyer G, Kramer G. Assmann I. Phenotypic characterization of infiltrating leukocytes in benign
313 prostatic hyperplasia. *Lab Invest.* 66: 96–107, 1992.
- 314 57. Ustinova EE, Fraser MO, Pezzone MA. Colonic irritation in the rat sensitizes urinary bladder
315 afferents to mechanical and chemical stimuli: an afferent origin of pelvic organ cross-
316 sensitization. *Am J Physiol Renal Physiol;* 290: F1478-1487, 2006.
- 317 58. Ustinova EE, Gutkin DW, Pezzone MA. Sensitization of pelvic nerve afferents and mast cell
318 infiltration in the urinary bladder following chronic colonic irritation is mediated by neuropeptides.
319 *Am J Physiol Renal Physiol.* 292: F123-130, 2007.

- 320 59. Ventura S, Lau WA, Buljubasich S, Pennefather JN. Calcitonin gene-related peptide (CGRP)
321 inhibits contractions of the prostatic stroma of the rat but not the guinea-pig. *Regul Pept* 91: 63–
322 73, 2000.
- 323 60. Verma V, Sharma V, Singh V, Kumar R, Khan MF, Singh AK, Sharma R, Arya KR, Maikhuri JP,
324 Dalela D, Maurya R, Gupta G. Labda-8(17),12,14-trien-19-oic acid contained in fruits of
325 Cupressus sempervirens suppresses benign prostatic hyperplasia in rat and in vitro human
326 models through inhibition of androgen and STAT-3 signaling. *Phytother Res.* 28(8): 1196-203,
327 2014.
- 328 61. Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and
329 metabolic syndrome. *Nat Rev Urol.* 13(2):108-19, 2016.
- 330 62. Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, Santi R, Filippi S,
331 Sebastianelli A, Nesi G, Serni S, Carini M, Maggi M. PDE5 inhibitors blunt inflammation in
332 human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. *Prostate.*
333 73(13):1391-402, 2013.
- 334 63. Weiss JP, Wein A, Jacobs J, Hanno PM. Use of nitrofurantoin macro-crystals after transurethral
335 prostatectomy. *J Urol.* 130:479, 1983.
- 336 64. Wong L, Hutson PR, Bushman W. Prostatic inflammation induces fibrosis in a mouse model of
337 chronic bacterial infection. *PLoS One.* 9(6): e100770, 2014.
- 338 65. Wong L, Hutson PR, Bushman W. Resolution of chronic bacterial-induced prostatic
339 inflammation reverses established fibrosis. *Prostate.* 75(1): 23-32, 2015.

340

341

342

Figure 1. (DeMarzo et al. 2008) Prostatic inflammation has numerous potential causes, including infectious agents, dietary habits, hormonal changes, and physical trauma and urinary reflux.

Drug Class	Proposed Mechanism	Examples	Current Status
Alpha-adrenergic antagonists	<ol style="list-style-type: none"> 1. Smooth muscle relaxation 2. Anti-nociceptive 3. Anti-inflammatory-uncertain mechanism 	Alfuzosni Prazosin Doxazosin Tamsulosin Terazosin	Approved First Line Therapy
5-alpha reductase inhibitors	<ol style="list-style-type: none"> 1. Blockade of DHT synthesis from T 2. Anti-inflammatory-uncertain mechanism 	Finasteride Dutasteride	Approved
NSAIDs	Blockade of prostaglandin synthesis	Naproxen Ibuprofen Celecoxib	Approved, OTC Often suggested by Physician
Phosphodiesterase 5 inhibitors	Inhibition of Type 5 PDE isoform <ol style="list-style-type: none"> 1. Smooth muscle relaxation 2. Blockade of leukocyte infiltration 	sildenafil tadalafil	Approved
Purinoreceptor antagonists	Blockade of P2X1-purinoreceptors		In development
Anti-histamine	Anti-inflammatory action at H1 receptors	Numerous OTC	Approved, OTC Often suggested
Endothelin antagonists	Blockade of inflammatory infiltrate at ET receptors	Ambrisentan Atrasentan Bosentan	Off label Approved for cancer
Rho Kinase inhibition	Blockade of inflammatory infiltrate by small GTPase inhibition		In development

Table 1: A summary of current pharmacological therapies for BPH targeting components of inflammation or inflammatory signaling.

343
 344
 345
 346

